Esperion Therapeutics (NASDAQ:ESPR) Upgraded at Wall Street Zen

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Sunday.

Other analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, June 17th. Needham & Company LLC cut their price objective on Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Esperion Therapeutics Trading Down 1.0%

Esperion Therapeutics stock opened at $2.05 on Friday. The firm has a market cap of $413.32 million, a price-to-earnings ratio of -4.18 and a beta of 0.82. The stock has a fifty day simple moving average of $1.33 and a two-hundred day simple moving average of $1.31. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%. The company had revenue of $82.39 million during the quarter, compared to analyst estimates of $62.55 million. On average, equities research analysts forecast that Esperion Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Two Seas Capital LP grew its holdings in Esperion Therapeutics by 43.6% during the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after purchasing an additional 3,024,104 shares during the period. Marshall Wace LLP grew its holdings in Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after purchasing an additional 1,679,294 shares during the period. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 3.1% during the second quarter. Geode Capital Management LLC now owns 4,583,988 shares of the biopharmaceutical company’s stock valued at $4,513,000 after purchasing an additional 137,691 shares during the period. Two Sigma Advisers LP grew its holdings in Esperion Therapeutics by 0.4% during the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after purchasing an additional 16,100 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in Esperion Therapeutics by 48.6% during the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after purchasing an additional 1,020,243 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.